|Synonyms:||TICAGRELOR;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol;Azd 6140;Unii-glh0314rvc;(1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)aMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;AR-C 126532XX;Ticagrelor(AR-C 126532XX;Ticagrelor (AZD6140)|
|Product Categories:||Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Ticagrelor;AZD6140;Cardiovascular APIs|
|TICAGRELOR Chemical Properties|
|TICAGRELOR Usage And Synthesis|
|Antiplatelet Aggregation Drug||Ticagrelor is a new kind of antiplatelet aggregation drug. It was successfully researched and developed by the United States company-AstraZeneca, and is the world's first reversible type combined with oral P2Y12 ADP receptor antagonist, the drug has reversible effect on vascular smooth muscle cells (VSMC) on purinoceptor 2, P2, don't need metabolic activation, has obvious inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), working quickly after been taken by oral, and can effectively improve symptoms of patients with acute coronary heart disease (CHD). Unlike thiophene and pyridine drugs, ticagrelor is reversible inhibitor for P2Y12 receptor, so it is particularly applicable for those patients that should be carried out in the early anticoagulation therapy after surgery.|
Astrazeneca's started developing Ticagrelor since 1999, the European heart association (ESC)firstly released Ⅲ period test results in 2009, which detailed compared the effects on patients with acute coronary syndrome (ACS).
In November 2009, Astrazeneca submitted new drug applications for Ticagrelor to the European Union and the United States, respectively.
Ticagrelor was approved used in adult patients with acute coronary syndrome (ACS) thrombosis incident prevention of atherosclerosis by the European Union in December 2010.
On December 17, 2010, the United States food and drug administration (FDA) has again decided to postpone approval of astrazeneca's new antiplatelet drugs for ticagrelor, and FDA lettered to require the company to provide additional analysis about the research on platelet inhibition and the prognosis of patients.
In January 2011, ticagrelor was officially sold in all EU member states, commodity name Brilique, the specification is 90 mg/piece, 60 slices of pack.
On July 20, 2011, Astrazeneca announced that the FDA has approved for ticagrelor to reduce cardiovascular death in patients with acute coronary syndrome (ACS) and heart attacks.
So far, ticagrelor has been approved for sale in 41 countries, and included in the seven countries, such as the UK medical compensation scope.
|Clinical Assessment||Ticagrelor gained the approval of the United States Food and Drug Administration (FDA) based on PLATO clinical research results. The test results are published in 2010 in the Lancet journal. PLATO is a multi-study center including 43 countries, 862 center, randomized, double-blind, 18624 cases of patients in the hospital due to acute coronary symptoms. All patients were randomly given aspirin combined ticagrelor or aspirin combined with clopidogrel antiplatelet therapy. The results showed that compared with patients taking clopidogrel, patients taking Ticagrelor had a 16% lower risk of heart attack, stroke, or death. PLATO experiments proved that Ticagrelor improves the survival rate for patients with benefits, and is now also widely recommended as a treatment strategy for acute coronary syndrome. In addition, ticagrelor reduced myocardial infarction and thrombosis related to implantation at the same time, does not increase the fatal bleeding events and overall risks of other serious adverse reactions.|
Although Ticagrelor shows superiority than Clopidogrel in PLATO clinical study, but it has two shortcomings: one is to take two times a day, rather than clopidogrel’s once a day; The second is Ticagrelor can significantly cause more adverse reactions such as difficulty in breathing than Clopidogrel. The half-life for Ticagrelor is only 12 hours, patients must take medicine twice a day, and this is too challenge. After all, not all patients are able to fully comply with this way of drug delivery. Results showed that about 20% of patients treated with clopidogrel did not follow the doctor's advice, these patients are less likely accordance strictly with the provisions dose when using Ticagrelor. Therefore, as a quick reversal drugs, direct drug withdrawal is likely to increase the risk of patients with acute thrombosis, which leads to heart attack or stroke.
|Patent Situation||Compound patent in China: CN1334816, patents expire time: on February 6, 2020.|
Foreign patents: Ticagrelor compound patents, due on December 2, 2019; Crystal type patent, due on May 31, 2021.
This information is edited by ChemicalBook Xiao Nan.
|Market Analysis||In recent years, with the development of social economy and the improvement of people's living standards, the incidence of thrombosis diseases is rising year by year, and the growing aging population, driving the market further. Myocardial infarction is the highest fatality rate disease, cerebral infarction is the highest morbidity of disease, the malignant disease all have direct relationship with thrombosis. So, the development speed of antithrombotic drug market is very fast, and has became one of the hottest areas of the global drug development.|
According to IMSHealth’s statistics, the sale of antithrombotic drug around the world in 2008 was about $18 billion, compared with the previous year increased by 16%. In China, the buying medicine amount of antithrombotic drugs in hospital has increased from 2.3 billion yuan to 2.3 billion yuan in the four years before September 2009 with an average annual growth of 32%. In the four years, more than double the size of the market strength with a good development momentum. At present, the clinical use of antiplatelet aggregation drugs-Bristol-Myers Squibb and Sanofi-Aventis Plavix (Clopidogrel) have become an popular in annual sales for billions of dollars, and Eli Lilly and Effient approved by FDA are potential competitors, but Astrazeneca's push for Ticagrelor is expected to become confrontation to oral antiplatelet aggregation and antithrombotic drug.
Ticagrelor’s chemical structure is cyclopentyl triazophos pyrimidine. It is the first oral reversible ADP receptor antagonist, can act directly on the P2Y12 receptor without metabolic activation. Research shows that compared with Clopidogrel, Ticagrelor can significantly reduce the patients with myocardial infarction, stroke, or cardiovascular death, etc. The severe bleeding complications did not increase. Studies have also shown that Ticagrelor had different effect way with Clopidogrel. Irreversible effects of Clopidogrel on the platelets, platelet keeps within a week, but stoppes after treatment, the effect is weakened or reverse soon, and platelets will rise in two days. The difference is very important for patients with excessive bleeding in the operation. Quick reversal is more suitable for coronary artery bypass graft surgery after medication, or has more vascular lesions and may accept bypass surgery patients. The poor compliance of patients is a challenge, leak drugs could lead to heart attack or stroke.
Ticagrelor will compete with Clopidogrel whoes sales were $9.3 billion in 2009. But Clopidogrel will lose patent protection in the United States in 2012, the patent expired in parts of Europe, provides a rare Ticagrelor market. The analysts predict that by 2014, Ticagrelor sales will reach $1.95 billion.
Used to reduce cardiovascular death in patients with acute coronary syndrome (ACS) and heart attacks.
|Chemical Properties||White Solid|
|Usage||Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)|
|Usage||Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively|
|TICAGRELOR Preparation Products And Raw materials|